Full Year 2023 Investor Presentation

7 Investor presentation Full year 2023 Novo NordiskⓇ International Operations diabetes care sales growth is driven by GLP-1 performance Reported Diabetes care sales and growth per IO geography DKK billion 80 20% GLP-1 patients and value market share in IO Insulin GLP-1 Growth at CER Number of patients (millions) Value market share Class growth >25% 8 75% 71.2% | 60 60 53% 20% 40 40 6 Geographical regions 42% 27% 20 20 0% 13% 2 61% 79% 3% -7% 4% 0 0 Nov IO EMEA China ROW 2021 Nov 2022 60% 47.5% 45% 26.9% 30% 13.9% 15% 9.7% 0.5% 0% Nov 2023 -VictozaⓇ NN GLP-1 GLP-1 patients OzempicⓇ -Rybelsus ―dulaglutide -tirzepetide IO: International Operations; NN: Novo Nordisk; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of World; CER: Constant exchange rates Note that the market share and patient numbers are based on countries with IQVIA coverage. GLP-1 class growth calculated as Sep'23-Nov/23 vs Sep'22-Nov 22 (Rolling 3-month average) Source: IQVIA MAT, Nov 2023 (Spot rate). Volume packs are converted into full-year patients based on WHO assumptions for average daily doses; Market values are based on the list prices

View entire presentation